Navigation Links
PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach
Date:7/28/2009

LEIDEN, The Netherlands, July 29, 2009 The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Dutch biopharmaceutical company Crucell N.V. today announced a collaboration to accelerate development of a promising type of malaria vaccine. Through funding from the USAID MVDP, the partners will conduct studies to determine the effectiveness of Crucell's novel prime-boost vaccine approach against the malaria parasite, Plasmodium falciparum. This approach uses Crucell's proprietary recombinant adenoviruses (a type of virus associated with the common cold and other mild respiratory infections) to deliver a malaria antigen to the immune system.

Dr. Jaap Goudsmit, Chief Scientific Officer at Crucell, commented, "This agreement is a strong validation of Crucell's malaria vaccine approach. We are excited to have MVI as our partner and to have the support of USAID. The fact that MVI is backing our program testifies to the importance of our efforts to further progress the development of Crucell's malaria vaccine."

For MVI, this partnership adds to its existing portfolio a vaccine approach with the potential to elicit a more comprehensive immune response than has been seen to date from the circumsporozoite protein (CSP), the only antigen that has proven to be protective against malaria in controlled challenge studies and field studies. Using Crucell's AdVac technology with two different vectorsthe adenovirus serotypes Ad35 and Ad26 as delivery mechanisms, this approach seeks to elicit a protective immune response obtained from delivering the CSP. The safety, immunogenicity and efficacy data from these studies will further advance the research forward development of a safe and highly efficacious malaria vaccine.

"Adenoviruses are one of the most potent vaccine delivery systems tested to date in humans. We are excited about the potential of Crucell's adenovirus-based program and the novel Ad35/Ad26 approach. The prime-boost regimen may be a critical next step in malaria vaccine development and, if successful, could move us toward our goal of having an 80 percent efficacious vaccine in use by 2025," said MVI Director, Dr. Christian Loucq.

Crucell is developing a recombinant malaria vaccine, Ad35-CS, based on the company's AdVac technology and PER.C6 manufacturing platform. The vaccine candidate is made by inserting the CSP gene from the P. falciparum malaria parasite into adenoviral vectors, which act as a 'vehicle' for vaccination delivery. This prime vaccine candidate is currently being tested in a Phase 1 study in partnership with the National Institute of Allergy and Infectious Diseases. This new collaboration will make it possible to clinically develop the Ad26 boost component of the vaccine and allow Crucell to further strengthen and expedite its malaria development program.

Carter Diggs at the USAID MVDP said, "We are pleased to support this adenovirus approach, which could play a vital role in malaria vaccine development."


'/>"/>

Contact: Preeti Singh
psingh@burnesscommunications.com
301-652-1558 x5722
Burness Communications
Source:Eurekalert

Related medicine news :

1. Counterfeit antimalarial drug discovered in Ghana
2. New global subsidy for malaria medicines must ensure quality of care
3. Miles To End Malaria Program Gets an Extra Burst of Speed From American Le Mans Series Founder Don Panoz
4. Global Fund Increases AIDS, Tuberculosis and Malaria Prevention and Treatment Measures by 30-50% Over One Year
5. Marathon and Partners Announce Dramatic Results of Malaria Control Project on Bioko Island in Equatorial Guinea
6. Deploying the Power of Music to Save Lives West Africas Most Beloved Singer Raises His Voice to End Malaria
7. House Subcommittee Markup Leaves Global Fund to Fight AIDS, TB, and Malaria in Crisis
8. Washington, DC Community Leaders Commit to Send 10,000 Anti-Malarial Bed Nets to Refugees in Africa
9. Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment
10. Simple blood test proves powerful ally in the fight against malaria
11. UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: Meadows Regional ... – Somers Point, NJ. The new clients range in bed size from 57 to ... solution and its interoperability. , Houston Methodist is a leading academic medical center comprised ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Dr. Charles ... and Dentistry of New Jersey in the class of 1986, where he graduated in ... dentistry at his current location in Livingston since 1989. He has been a member ...
(Date:5/31/2016)... ... May 31, 2016 , ... Super Powder, a supplement produced by Prox Formulas ... and dedicated athletes, continues to transform the nutritional supplement industry by providing a safe, ... protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit ...
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin Institute officially starts ... 8-night special intensive summer training camp starts on June 17th on Shaolin Institute ... and children a fun and unique experience with an opportunity to learn KungFu ...
(Date:5/29/2016)... ... ... "With 30 unique self-animating web themed intros and complete control over customization, ... Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume 3 ... Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a sleek ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... 30, 2016 The global  ... 7.3 billion by 2024, according to a new ... natality rate, the growing malnutrition coupled with the ... gastro-intestinal tract diseases are expected to boost the ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
(Date:5/30/2016)... 2016 LifeScienceIndustryResearch.com adds "Ulcerative ... report with comprehensive information on the therapeutic development ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Ulcerative ...
(Date:5/27/2016)... CAESAREA, Israel , May 27, 2016 ... developer of the Dario™ Diabetes Management Tool, today announced that ... present at the Marcum MicroCap Conference being held June 1-2 ... LD Micro Invitational, being held June 7-9 in ... Mr. Ben-David will discuss recent corporate and operational milestones, including ...
Breaking Medicine Technology: